• Product mockup
  • Product mockup
  • Product mockup
  • Product mockup
  • Product mockup
  • Product mockup
1 6

The Purple Sky Store

Men's Wind Breaker Jacket (Embroidered Purple Ribbon)

Men's Wind Breaker Jacket (Embroidered Purple Ribbon)

$64.00 USD
$64.00 USD
Sale Sold out
Shipping calculated at checkout.
Color
Size
Face any weather with confidence and purpose in the Champion Element Support Packable Jacket. This wind and rain-resistant jacket is crafted from 100% polyester micro poplin to keep you protected from the elements, and it’s designed to be as practical as it is stylish. Featuring a hood, front kangaroo pocket, and a hidden zipped pouch pocket, this jacket can be conveniently packed into itself, making it perfect for on-the-go storage.

Beyond its functionality, this jacket serves a meaningful cause. 40% of all revenue from the Champion Element Support Packable Jacket goes to Sky Foundation, a non-profit that funds pancreatic cancer research, allowing you to make a positive impact with every wear.

100% polyester micro poplin for wind and rain resistance
Half zip pullover design with adjustable bungee draw cords at hood and hem
Front kangaroo pocket and hidden zipped pouch pocket for convenience
Packable design fits into its own zipped pocket for easy storage
Elastic cuffs for a snug fit
View full details

Recent News

View all
  • Phase 1/2 Trial Launches for Innovative Pancreatic Cancer Immunotherapy

    Phase 1/2 Trial Launches for Innovative Pancrea...

    UCSF researchers begin testing novel TCR-T cell therapy targeting KRAS mutations in advanced pancreatic cancer. A new clinical trial at UCSF has opened to test a first-of-its-kind immunotherapy for advanced...

    Phase 1/2 Trial Launches for Innovative Pancrea...

    UCSF researchers begin testing novel TCR-T cell therapy targeting KRAS mutations in advanced pancreatic cancer. A new clinical trial at UCSF has opened to test a first-of-its-kind immunotherapy for advanced...

  • FDA Approves NALIRIFOX as First-Line Treatment for Metastatic Pancreatic Cancer

    FDA Approves NALIRIFOX as First-Line Treatment ...

    New frontline treatment offers hope with improved survival outcomes for advanced PDAC patients The U.S. Food and Drug Administration (FDA) has officially approved NALIRIFOX, a new frontline therapy for patients with metastatic...

    FDA Approves NALIRIFOX as First-Line Treatment ...

    New frontline treatment offers hope with improved survival outcomes for advanced PDAC patients The U.S. Food and Drug Administration (FDA) has officially approved NALIRIFOX, a new frontline therapy for patients with metastatic...

  • Immunotherapy for Pancreatic Ductal Adenocarcinoma: Barriers and Opportunities

    Immunotherapy for Pancreatic Ductal Adenocarcin...

    Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers, with a 5-year survival rate under 10%. Standard treatments like surgery and chemotherapy often fail because the cancer usually comes...

    Immunotherapy for Pancreatic Ductal Adenocarcin...

    Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers, with a 5-year survival rate under 10%. Standard treatments like surgery and chemotherapy often fail because the cancer usually comes...

1 3
View all